The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of KIT mutations with risk of central nervous system (CNS) metastasis (met) in patients (pts) with mucosal melanoma (MM).
 
Afsaneh Amouzegar
No Relationships to Disclose
 
Merve Hasanov
Honoraria - Curio Science (I)
Consulting or Advisory Role - Eisai (I); Pfizer (I); Telix Pharmaceuticals (I)
 
Ahmed Ali
No Relationships to Disclose
 
Denai Milton
No Relationships to Disclose
 
Julie Simon
No Relationships to Disclose
 
Jene Samuels
No Relationships to Disclose
 
Khalida Wani
No Relationships to Disclose
 
Debora Ledesma
No Relationships to Disclose
 
Elizabeth Burton
No Relationships to Disclose
 
Courtney Hudgens
No Relationships to Disclose
 
Hussein Tawbi
Consulting or Advisory Role - Boxer Capital; Bristol-Myers Squibb; Genentech/Roche; IO Biotech; Iovance Biotherapeutics; Jazz Pharmaceuticals; Medicenna; Merck; Novartis; Pfizer; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Dragonfly Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); RAPT Therapeutics (Inst); Regeneron (Inst)
 
Jeffrey Gershenwald
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Novartis; Novartis; Regeneron; Syndax
Patents, Royalties, Other Intellectual Property - mercator therapeutics; UpToDate
 
Alexander Lazar
Leadership - Archer; Iterion Therapeutics; Nucleai
Stock and Other Ownership Interests - Archer; Beta Cat Pharmaceuticals; PAIGE.AI
Honoraria - Bristol-Myers Squibb; Genentech/Roche; Janssen Oncology; Novartis
Consulting or Advisory Role - Abbvie; Bayer; Bristol-Myers Squibb; Deciphera; Novartis
Research Funding - AstraZeneca/UK; MedImmune; Novartis; Roche
Patents, Royalties, Other Intellectual Property - Elsevier
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
 
Michael Davies
Consulting or Advisory Role - ABM; Apexigen; Array BioPharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; Iovance Biotherapeutics; NanoString Technologies; Novartis; Nurix; Pfizer; Replimune
Research Funding - ABM (Inst); AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lead Pharma (Inst); Merck (Inst); Myriad Genetics (Inst); Oncothyreon (Inst); Pfizer (Inst); Sanofi (Inst)